Eosinophilic Esophagitis: Diet or Steroids — Which Works Better?

Research-informed explainer — last updated April 12, 2026

If you have eosinophilic esophagitis (EoE), you likely face a choice that no one prepared you for: try removing foods from your diet to find the trigger, or take a topical steroid to suppress the inflammation. Both approaches can work. Neither works for everyone. And for many patients, the answer turns out to be a combination of the two, or — more recently — a biologic injection that addresses the underlying immune pathway driving the disease.

This explainer draws on research from five esophageal disease specialists in the Convene directory. Evan Dellon at UNC directs the Center for Esophageal Diseases and Swallowing and led development of the updated EoE consensus recommendations and the ACG Clinical Guideline. Nirmala Gonsalves at Northwestern published the landmark randomized trial establishing elimination diet as effective treatment for adults, including the systematic reintroduction protocol that identifies which foods are the actual triggers. Gary Falk at Penn directed esophageal research including the immune mechanism work showing how TSLP and basophils drive EoE — the same pathway now targeted by dupilumab. William Faubion at Mayo Clinic Arizona published the foundational pediatric study on using inhaled corticosteroids (swallowed) to treat EoE. Nicholas Shaheen at UNC has contributed to long-term outcomes and esophageal disease burden research.

What is eosinophilic esophagitis

EoE is a chronic immune-mediated disease where eosinophils — a type of white blood cell involved in allergic responses — accumulate in the lining of the esophagus. They don't belong there in significant numbers, and their presence triggers inflammation, tissue damage, and eventually scarring that stiffens the esophagus wall.

The main symptom in adults is food getting stuck in the esophagus (dysphagia) or food impaction events where something lodges and won't pass. In children, symptoms are different — they often present with failure to thrive, feeding problems, reflux-like symptoms, or vomiting. The condition is strongly associated with other allergic diseases: asthma, eczema, hay fever, and food allergies are all more common in people with EoE than in the general population.

Diagnosis requires an endoscopy with biopsies from the esophagus. The defining threshold is 15 or more eosinophils per high-power microscope field on biopsy. Endoscopic findings may include rings, furrows, white plaques (small deposits of eosinophil debris), and narrowing of the esophagus.

EoE is not rare. Prevalence in the United States is estimated at 1 in 2,000 people and rising, driven partly by better recognition and partly by true increases in atopic disease [1].

What is the difference between these treatments?

The two main first-line treatment categories for EoE are fundamentally different in both mechanism and what they ask of you.

Elimination diets work by removing common food triggers from your diet — usually the six foods most likely to cause EoE (milk, wheat, egg, soy, nuts, and seafood). Without the antigen driving the immune response, the eosinophil counts in the esophagus drop, symptoms improve, and biopsies show resolution. Foods are then reintroduced one at a time, each followed by repeat endoscopy and biopsy, to identify your specific triggers. This process identifies the trigger and potentially allows you to eat most foods again, but it requires multiple endoscopies and significant dietary restriction for months.

Topical steroids work by delivering a corticosteroid — fluticasone or budesonide — directly to the esophageal lining in swallowed form. These are not oral systemic steroids; they act locally with minimal absorption. They suppress the eosinophilic inflammation regardless of what's triggering it. They work faster than dietary management, don't require eliminating foods, and don't need repeated endoscopies for the identification phase. But they don't cure the underlying allergy, and the disease usually returns if you stop them.

At a glance

When elimination diet is the better choice

Elimination diet makes the most sense if you strongly prefer not to use ongoing medication, if you have other food allergies you're managing anyway, or if you want to identify your exact triggers so you can potentially eat freely once they're known.

The landmark randomized trial by Nirmala Gonsalves and colleagues at Northwestern, published in Gastroenterology, enrolled 52 adults with EoE and studied the six-food elimination diet [3]. The histologic remission rate — defined as fewer than 15 eosinophils per high-power field — was 73% on the diet. When foods were reintroduced one at a time, the most common triggers were grains (wheat) and dairy. After identifying triggers and removing only those foods, 64% of patients maintained histologic remission while eating everything else. This is the best evidence that dietary management works in adults and that targeted elimination (just avoiding your triggers) is more practical long-term than eliminating all six food groups.

The limitation is the process. Identifying your trigger foods requires repeating endoscopy after each food is reintroduced — potentially four to six additional procedures over six to twelve months. That's a meaningful burden for patients and limits how many people actually complete the full reintroduction sequence. A step-up approach — starting with two- or four-food elimination rather than all six — has shown good results in studies and reduces the overall scope of dietary restriction.

When topical steroids are the better choice

Steroids are typically preferred for patients who need rapid symptom relief, can't do the multiple-endoscopy reintroduction protocol, have complex dietary restrictions already, or simply want an easier first step to see if the disease can be controlled.

The evidence for topical steroids in EoE goes back to foundational work by William Faubion and colleagues, who published the first description of using swallowed inhaled corticosteroids — specifically fluticasone — for pediatric EoE patients in 1998 [7]. At the time this was a novel approach, repurposing an asthma medication by having patients swallow the puff rather than inhale it, delivering the drug to the esophagus. In subsequent trials, both fluticasone (swallowed MDI) and budesonide (oral viscous suspension or ODT tablet) showed remission rates of approximately 50-70%.

A key distinction: budesonide oral dispersible tablets (Jorveza in Europe; EohiliaRx in the US) and budesonide oral suspension (Eohilia, the first FDA-cleared drug for EoE) are now available as formulations specifically designed to coat the esophagus and dissolve on contact. These purpose-built formulations produce better mucosal contact than swallowed asthma MDIs, which is why remission rates in recent trials using dedicated EoE formulations have generally been higher.

The downside of steroids: they don't address the underlying immune trigger, so disease typically recurs when therapy is stopped. Most patients need ongoing maintenance treatment.

What is changing: dupilumab

In 2022, the FDA approved dupilumab (Dupixent) specifically for EoE in adults and adolescents — the first biologic approved for this disease. Dupilumab blocks the receptor for both IL-4 and IL-13, two cytokines that drive the type 2 immune response at the core of EoE. It's the same drug already approved for atopic dermatitis, asthma, and nasal polyps — all conditions driven by the same immune pathway.

The approval was based on the PART 1/PART 2 trial showing that dupilumab at 300 mg every 2 weeks achieved histologic remission in approximately 53% of patients at 24 weeks, compared to 2% for placebo — with significantly greater symptom improvement in swallowing as well. In a subset of patients with both EoE and atopic dermatitis, dupilumab addressed both conditions simultaneously, which is clinically useful.

Gary Falk's team at Penn published research identifying the upstream immune mechanism that dupilumab targets: TSLP (thymic stromal lymphopoietin), an epithelial-derived cytokine, triggers basophils that in turn drive the eosinophilic response in the esophagus [6]. This TSLP-basophil-eosinophil axis is the pathway dupilumab disrupts through IL-4/IL-13 blockade.

Dupilumab is the most convenient treatment option — a subcutaneous injection every two weeks, no diet changes required, no oral medication with swallowing constraints. The main limitations are cost (it's a biologic, so expensive, and prior authorization requirements vary) and the fact that it's a long-term commitment rather than a cure.

Esophageal dilation: not a treatment for EoE, but useful for strictures

A point of confusion for many patients: esophageal dilation — stretching the esophagus with a balloon or dilator during endoscopy — is not a treatment for EoE inflammation. It does not reduce eosinophil counts or address the disease itself. But it can provide rapid symptom relief for patients who have developed a fibrostenotic narrowing (a stricture) that makes swallowing severely impaired.

Research by Nirmala Gonsalves and colleagues showed that dilation is safe in EoE when done carefully, with a low rate of serious complications, and that it doesn't worsen the underlying inflammation [4]. Current guidelines support dilation as an adjunct to anti-inflammatory therapy when strictures are present — but dilation alone, without treating the underlying disease, leads to re-narrowing over time.

How treatment decisions are made in practice

Most gastroenterologists and allergists who treat EoE follow a stepwise approach aligned with the ACG guideline that Evan Dellon helped develop [2]. The first question is: does the patient have a proton pump inhibitor (PPI)-responsive form? A trial of high-dose PPI is recommended before starting other treatments, because a subset of patients — those with PPI-responsive esophageal eosinophilia — will see resolution on PPI alone.

For patients who don't respond to PPIs, the choice of diet versus steroids is largely preference-driven and lifestyle-based. Allergist collaboration is helpful for patients with multiple co-existing atopic conditions.

Dupilumab is typically considered for patients who have not responded to or cannot tolerate diet and steroid approaches, or who have significant comorbid atopic disease. Its high cost and injection requirement are limiting factors for some patients.

Questions to ask your doctor

• Have I had a trial of high-dose PPI to rule out PPI-responsive eosinophilic esophagitis?
• Given my lifestyle and other health conditions, which approach — diet or steroids — makes more sense to try first?
• If I try the elimination diet, how many endoscopies should I expect before we identify my trigger foods?
• Is my esophagus already showing signs of narrowing, and would dilation help while we treat the inflammation?
• Am I a candidate for dupilumab — and if so, how do I navigate insurance prior authorization?
• If I go on topical steroids, how long would I need to stay on them, and what does monitoring look like?

The bottom line

Both elimination diet and topical steroids are effective first-line treatments for eosinophilic esophagitis, with histologic remission rates in the 50-73% range. Diet is the only approach that can identify and potentially eliminate your triggers, allowing trigger-free eating once those foods are identified — but it requires significant commitment and multiple endoscopies. Topical steroids work faster, require no dietary changes, but don't address the underlying allergy and typically require ongoing use. Dupilumab, FDA-approved since 2022, is the first biologic approved for EoE and is effective for patients who can't achieve adequate control with other approaches. The right choice depends on your symptoms, your lifestyle, your other allergic conditions, and how you weigh convenience against the possibility of identifying a permanent fix.